Novel genome editing strategy to treat genetic disorders

Start date project: 2023
Involved institutes: LUMC
Stage: Preclinical
Status: Ongoing

Description: For the genetic disorder Duchenne Muscular Dystrophy (DMD) there is currently no universal therapy available that stops the muscle deterioration. The aim of this project is to test a novel and precise gene editing approach for DMD patients with a variety of underlying mutations in the dystrophin gene. This technology could be applied in gene therapies for other genetic diseases and metabolic disorders as well.

Stay up to date with news, inspirations and events.

© Starfish Innovations. All rights reserved.